PlaqueTec, a medtech company developing diagnostics for cardiovascular disease through intracoronary liquid biopsy technology, has raised $5 million in an oversubscribed funding round from existing investors.
The capital will be used to expand the company’s proprietary BioCarta data platform, which combines proteomic and clinical datasets to improve understanding of inflammatory drivers behind coronary disease and support more precise treatment strategies.
What The Company Does
PlaqueTec focuses on advancing cardiovascular diagnostics by collecting biological data directly from the site of coronary plaque formation rather than relying solely on conventional peripheral blood samples. Its proprietary intracoronary liquid biopsy technology is designed to capture biomarkers from within the coronary arteries, offering a more targeted view of disease processes linked to atherosclerosis and inflammation.
The company’s core platform, BioCarta, aggregates these biological signals with clinical patient data to build a high-resolution dataset focused on coronary artery disease. By analysing biomarkers closer to the source of disease activity, PlaqueTec aims to identify patient sub-groups with distinct inflammatory profiles and help clinicians make more informed treatment decisions.
This site-of-disease approach is intended to improve risk stratification, diagnostic accuracy, and therapeutic targeting in one of the world’s leading causes of death.
Advertisement
Market Context / Industry Background
Cardiovascular disease remains the leading global cause of mortality, yet many diagnostic tools still rely on broad risk factors and indirect biomarkers rather than direct biological signals from affected arteries. As healthcare moves toward precision medicine, there is increasing demand for more specific diagnostic approaches that can identify which patients are most at risk and which therapies are most likely to work.
Inflammation has become a major focus in cardiovascular research, particularly in coronary artery disease where plaque instability can lead to heart attacks and other serious events. Pharmaceutical companies are also investing in therapies that target inflammatory pathways, creating demand for better patient stratification tools and higher-quality biological datasets.
In this context, PlaqueTec is positioning BioCarta not only as a diagnostic platform but also as a strategic data asset for drug development partnerships and biomarker discovery.
Founder / Investor Commentary
PlaqueTec Chairman Martin Stapleton said the latest round reflects investor confidence in the company’s differentiated approach and the value of its emerging dataset.
“The decision by our existing shareholders to reinvest and to do so at a level that exceeded our target, speaks directly to their confidence in what PlaqueTec’s data is revealing about cardiovascular disease,” he said.
He added that the company is building “a high-resolution, intracoronary data asset” that could support the next generation of cardiovascular therapeutics, and that the new funding provides the runway to validate that strategy further.
Growth Plans / Use Of Funds
PlaqueTec will use the new capital to accelerate development of BioCarta and expand the volume of patient data generated through its ongoing BIOPATTERN clinical trial. The trial is collecting proteomic samples and clinical insights from a growing patient cohort using the company’s intracoronary liquid biopsy system.
According to the company, early analysis has already identified multiple potential therapeutic targets across specific sub-groups of coronary artery disease patients. Expanding the dataset may strengthen its value for pharmaceutical and biotech partners seeking better ways to select targets and identify patients most likely to benefit from future therapies.
PlaqueTec said it is already in active discussions with pharma and biotech companies interested in using intracoronary biological insights to improve cardiovascular drug development programs.
The funding is also expected to support broader commercial and research collaborations as the company builds out its role in precision cardiovascular medicine.
About PlaqueTec
PlaqueTec is a medtech company focused on improving the diagnosis and treatment of coronary artery disease through intracoronary liquid biopsy technology. The company develops data-driven tools that capture biomarkers directly from diseased coronary arteries, helping reveal the biological mechanisms behind cardiovascular conditions. Its BioCarta platform combines proteomic and clinical data to support precision medicine, risk stratification, and next-generation cardiovascular therapies.
